Top

Published in:

01-04-2024 | Atovaquone | Media release

Atovaquone oral suspension USP 750 mg/5mL: recall due to microbial contamination

Published in: Reactions Weekly | Issue 1/2024

Excerpt

A recall of one lot of atovaquone oral suspension USP 750 mg/5mL has been announced by the company AvKARE, LLC, according to a media release issued on 1 April 2024 by the US Food and Drug Administration (FDA). …

US Food & Drug Administration (FDA). AvKARE, LLC. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750 mg/5 mL Due to Potential Bacillus Cereus Contamination. Internet Document : 1 Apr 2024. Available from: URL: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/avkare-llc-issues-voluntary-nationwide-recall-atovaquone-oral-suspension-usp-750-mg5-ml-due

Title: Atovaquone oral suspension USP 750 mg/5mL: recall due to microbial contamination
Publication date: 01-04-2024
Publisher: Springer International Publishing
Keyword: Atovaquone
Published in: Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-024-56642-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Atovaquone oral suspension USP 750 mg/5mL: recall due to microbial contamination

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2024

Bevacizumab/Docetaxel/Gemcitabine

Multiple drugs

Calcitriol/Colecalciferol

Calcium/vitamin-D

Atezolizumab/Bevacizumab/Lenvatinib

Amrubicin/pegfilgrastim